Darrin Benjumea
Director | New York, US
Focus Area
Darrin focuses in the design and implementation of Integrated Evidence Planning frameworks and strategy. He is an experienced healthcare strategist and consultant, specializing in real-world evidence (RWE) and HEOR tactics and strategies, with heavy prior experience in developing evidence for the access and reimbursement of therapies for solid-tumor oncology and rare diseases.
He has led and supported the development and execution of integrated evidence generation plans and subsequent evidence activities to demonstrate product value across product lifecycle stages and patient, physician, payer, and policy audiences.
Education
MPH (Epidemiology) - Columbia University, New York, USA
BS (Biochemistry) - University of North Carolina at Chapel Hill, North Carolina, USA
Languages
English, French, Spanish, Kabyle
Select Peer-reviewed publications
Rare Disease:
Loftus J, Wogen J, Benjumea D, Jhingran P, Chen Y, Alvir J, Majnrajch MP, Takasawa K.
Persistence with daily growth hormone among children and adolescents with growth hormone deficiency in Japan.
PLoS One. 2025;20(8):e0324728. Published 2025 Aug 14. doi:10.1371/journal.pone.0324728
Loftus J, Wogen J, Oliveri D, Benjumea D, Jhingran P, Chen Y, Alvir J Rivero-Sanz E, Kowalik JC, Wajnrajch MP.
Persistence with daily growth hormone among children and adolescents with growth hormone deficiency in the UK.
Front Endocrinol (Lausanne). 2022;13:1014743. Published 2022 Nov 3. doi:10.3389/fendo.2022.1014743
Miller BS, Loftus J, Kelkar M, Shrestha S, Parzynski C, Benjumea D, Wogen J, Jhingran P, Alvir J, Gupta A, Wajnrajch M.
Impact of Daily Growth Hormone Adherence on Height Velocity Among Children With Growth Hormone Deficiency (GHD)
Endocr Pract. 2024 Sep;30(9):837-846. doi: 10.1016/j.eprac.2024.05.012. Epub 2024 May 29. PMID: 38821179.
Masri A, Chen Y, Colavecchia AC, Benjumea D, Crowley A, Jhingran P, Kent M, Wogen J, Pankratova C, Alvir J, Bhambri R.
Coexisting Calcific Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Real-World Evaluation of Clinical Characteristics and Outcomes.
J Am Heart Assoc. 2025;14(2):e033251. doi:10.1161/JAHA.123.033251
Kato T, Ines M, Minamisawa M, Benjumea D, Keohane D, Alvir J, Kim R, Chen Y, Peixoto T, Kent M, Wogen J, Ishii T, Crowley A, Sugino T, Izumiya Y.
Tafamidis medication adherence and persistence in patients with transthyretin amyloid cardiomyopathy in Japan.
ESC Heart Fail. 2024 Oct;11(5):2881-2888. doi: 10.1002/ehf2.14736. Epub 2024 May 23. PMID: 38783561; PMCID: PMC11424365.
Bhambri R, Colavecchia AC, Bruno M, Chen Y, Alvir J, Roy A, Kemner J, Crowley A, Benjumea D, Gilstrap L.
Real-World Characteristics of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: An Analysis of Electronic Healthcare Records in the United States.
Am J Cardiovasc Drugs. 2023;23(2):197-206. doi:10.1007/s40256-022-00563-4
Roy A, Peterson A, Marchant N, Alvir J, Bhambri R, Bredl Z, Benjumea D, Kemner J, Parasuraman B.
Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with transthyretin amyloid cardiomyopathy and/or receiving tafamidis prescriptions: A retrospective analysis of a Medicare cohort.
J Manag Care Spec Pharm. 2022;28(7):766-777. doi:10.18553/jmcp.2022.28.7.766
Roy A, Peterson A, Marchant N, Alvir J, Bhambri R, Lynn J, Benjumea D, Prasad S, O’Brien A, Chen Y, Kemner J, Parasuraman B.
Baseline Characteristics and Secondary Medication Adherence Patterns Among Patients Receiving Tafamidis Prescriptions: A Retrospective Analysis Using a National Specialty Pharmacy Dispensing Database.
Patient Prefer Adherence. 2022;16:1115-1129. Published 2022 Apr 29. doi:10.2147/PPA.S352332
Oncology:
Moon HH, Aragon-Ching JB, Thompson A, Abraham A, Vlahiotis A, Ike C, Benjumea D, Shao A, Sun H, Kearney M, Gharibian N, Hanson S, Li B, Kirker M, Grivas P.
Early real-world utilization of avelumab switch maintenance among patients with advanced urothelial carcinoma without progression following treatment with first-line platinum-based chemotherapy.
Urol Oncol. Published online July 16, 2025. doi:10.1016/j.urolonc.2025.05.014
Moon HH, Kirker M, Abraham A, Vlahiotis A, Bhanegaonkar A, Ike C, Benjumea D, Kim C, Sun H, Kearney M, Chandrasekar S, Li B, Thakkar S.
Noninterventional retrospective study of standard-of-care systemic treatment patterns and outcomes in US patients with advanced urothelial carcinoma.
Oncologist. 2025;30(7):oyaf071. doi:10.1093/oncolo/oyaf071
Dennis MJ, Abrahami D, Vieira MC, Benjumea D, Boyd M, Shao A, Kelton J, Patel SP.
Real-World Analysis of Disparities in Biomarker Testing and Use of Recommended Targeted Therapies in Metastatic Non-Small Cell Lung Cancer in the United States.
JCO Precis Oncol. 2025;9:e2400449. doi:10.1200/PO-24-00449
Infectious Disease:
Scott A, Puzniak L, Murphy MV, Benjumea D, Rava A, Benigno M, Allen KE, Stanford RH, Manuel F, Chambers R, Reimbaeva M, Ansari W, Cha-Silva AS, Draica F.
Assessment of clinical characteristics and mortality in patients hospitalized with SARS-CoV-2 from January 2022 to November 2022, when Omicron variants were predominant in the United States.
Curr Med Res Opin. 2025;41(1):71-82. doi:10.1080/03007995.2024.2442515
Cai B, Tillotson G, Benjumea D, Callahan P, Echols R.
The Burden of Bloodstream Infections due to Stenotrophomonas maltophilia in the United States: A Large, Retrospective Database Study.
Open Forum Infectious Diseases. 2020; 1-7. https://doi.org/10.1093/ofid/ofaa141